Abstract 1512P
Background
Life expectancy has currently increased and pancreaticoduodenectomy (PD) is being performed more frequently on elderly patients in Japan. Surgical treatment for pancreatic ductal adenocarcinoma (PDAC) in patients over 80 years old is increasingly accepted, although it may lead to a decline in quality of life after surgery. Currently, there are no definitive indications for PD in octogenarians. This study aims to examine the surgical indications for PD in this age group, focusing on clinical background and perioperative and postoperative outcomes.
Methods
This retrospective analysis included patients with PDAC who underwent PD between 2012 and 2022. Patients aged ≥80 years were categorized as the Elderly (E) group, while those <80 years were classified as the Non-elderly (N) group. We compared clinical backgrounds, perioperative, and postoperative outcomes between the groups.
Results
PD was performed on 147 patients with PDAC. The median age was 71 years (range 45-85). Twenty-two patients (15.0%) were in the E group and 125 (85.0%) in the N group. The median Charlson comorbidity index (CCI) was significantly higher in the E group (6, range 5-10) compared to the N group (4, range 1-11; p
Conclusions
PD could be safely performed in elderly patients in good physical condition, with the survival benefit of PD for PDAC appearing as promising in elderly patients as in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Keio University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18
1468P - cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma
Presenter: Eileen Parkes
Session: Poster session 18
1469P - Development of an efficacy prediction model for concurrent chemoradiotherapy in esophageal squamous cell carcinoma using deep learning and multimodal data integration
Presenter: Xin Yang
Session: Poster session 18
1470TiP - Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Presenter: Eiji Oki
Session: Poster session 18
1471TiP - MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Presenter: Zev Wainberg
Session: Poster session 18
1472TiP - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial
Presenter: Nils Homann
Session: Poster session 18
1473TiP - Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients
Presenter: Zhen Yuan
Session: Poster session 18
1474TiP - A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Presenter: Ziyu Li
Session: Poster session 18